Critical bleeding in pregnancy: a novel therapeutic approach to bleeding

Published: June 5, 2009
Abstract Views: 322
PDF: 879
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Critical post-partum hemorrhage (PPH) occurs in 1/1,000 deliveries; hysterectomy 1/2,000; risk of death 1-2/100,000. The majority of the PPH have obstetrical causes, most frequently atony of the uterus. Hereditary and acquired hemostatic defects are very rare. The therapeutic intervention, to control the bleeding and its consequences, should be as early as possible. Guidelines of standard surgical and medical measures are available. rFVIIa has been successfully used in hemophilic patients with inhibitors and in critical bleeding of different causes. Preliminary anecdotal reports of its use in PPH after failure of conventional standard therapy suggest that rFVIIa should be administered as early as possible before the consequences of severe and intractable bleeding set in.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Baudo, F. (2009). Critical bleeding in pregnancy: a novel therapeutic approach to bleeding. Hematology Meeting Reports (formerly Haematologica Reports), 1(10). https://doi.org/10.4081/hmr.v1i10.347